5 Key Takeaways
-
1
CMS has finalized a 2.9% reimbursement increase for ASCs in 2025, acknowledging rising outpatient costs but not fully offsetting healthcare inflation.
-
2
ASCs face financial challenges due to reimbursement cuts and regulatory burdens, necessitating income supplementation through non-Medicare services.
-
3
New reimbursement caps for nonopioid pain management drugs may strain ASC finances, requiring careful resource management to avoid shortfalls.
-
4
2025 will see the expiration of pass-through status for certain ophthalmic drugs, complicating reimbursement and financial planning for ASCs.
-
5
ASCs must adapt to new health equity measures and potential prior authorization expansions, increasing administrative burdens and operational costs.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
